Akebia Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
Akebia Therapeutics (NASDAQ:AKBA) Third Quarter 2022 Results
Key Financial Results
Revenue: US$49.0m (flat on 3Q 2021).
Net loss: US$51.9m (loss narrowed by 13% from 3Q 2021).
US$0.28 loss per share (improved from US$0.34 loss in 3Q 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Akebia Therapeutics Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) missed analyst estimates by 93%.
Looking ahead, revenue is expected to decline by 33% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 14%.
Performance of the American Biotechs industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 4 warning signs we've spotted with Akebia Therapeutics (including 1 which is potentially serious).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
